Results 11 to 20 of about 245,752 (174)

High dupilumab levels in tear fluid of atopic dermatitis patients with moderate‐to‐severe ocular surface disease

Clinical and Translational Allergy, 2023
Background The patho‐mechanism of ocular surface disease (OSD) in dupilumab‐treated atopic dermatitis (AD) patients remains unclear. The aim of this study is to measure dupilumab levels in tear fluid and serum, and relate these findings to the severity ...
Roselie Achten, Judith Thijs, Marlot van derWal, Chantal vanLuijk, Matthijs vanLuin, Mohsin el Amrani, Edward Knol, Eveline Delemarre, Constance den Hartog Jager, Marlies deGraaf, Daphne Bakker, Joke deBoer, Femke vanWijk, Marjolein deBruin‐Weller   +13 more
doaj   +1 more source

Molecular Mechanisms of Atopic Dermatitis Pathogenesis

International Journal of Molecular Sciences, 2021
Atopic dermatitis is a chronic, non-infectious inflammatory dermatosis. Acharacteristic feature is persistent itching of the skin. The chronic, relapsing course of the disease, economic burden, and the whole family’s involvement in the treatment process ...
Jowita Sroka-Tomaszewska, M. Trzeciak
semanticscholar   +1 more source

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis

JAMA dermatology, 2021
Key Points Question Are the efficacy and safety of oral upadacitinib superior to subcutaneous dupilumab in adults with moderate-to-severe atopic dermatitis (AD)?
A. Blauvelt, H. Teixeira, E. Simpson, A. Costanzo, M. D. de Bruin‐Weller, S. Barbarot, V. Prajapati, P. Lio, Xiaofei Hu, Tianshuang Wu, John Liu, B. Ladizinski, A. Chu, K. Eyerich   +13 more
semanticscholar   +1 more source

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.

New England Journal of Medicine, 2021
BACKGROUND The oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces interleukin-4 and interleukin-13 signaling, is being investigated for the treatment of atopic dermatitis. Data from trials comparing JAK1 inhibitors with monoclonal antibodies,
T. Bieber, E. Simpson, J. Silverberg, D. Thaçi, C. Paul, A. Pink, Y. Kataoka, C. Chu, M. Dibonaventura, R. Rojo, J. Antinew, I. Ionita, R. Sinclair, S. Forman, Jacek Zdybski, P. Biswas, B. Malhotra, Fan Zhang, H. Valdez   +18 more
semanticscholar   +1 more source

Prevalence of Isotretinoin Therapy in Adolescents and Young Adults With and Without Atopic Dermatitis: A Nationwide Prescription-based Population Study

Acta Dermato-Venereologica, 2023
Although isotretinoin has anti-inflammatory and immunomodulatory properties, it can exacerbate atopic dermatitis. National estimates of the extent to which patients with atopic dermatitis are affected by severe acne and isotretinoin tolerability are ...
Cathrine H. Mohn, Hege S. Blix, Anja Maria Brænd, Per Nafstad, Jon Anders Halvorsen   +4 more
doaj   +1 more source

Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis

JAMA dermatology, 2022
This analysis of 2 randomized clinical trials evaluates long-term (52 weeks) efficacy and safety of upadacitinib treatment in patients with atopic dermatitis.
E. Simpson, K. Papp, A. Blauvelt, C. Chu, H. Hong, N. Katoh, B. Calimlim, J. Thyssen, A. Chiou, R. Bissonnette, L. S. Stein Gold, C. Wegzyn, Xiaofei Hu, Meng Liu, John Liu, A. Tenorio, A. Chu, E. Guttman‐Yassky   +17 more
semanticscholar   +1 more source

Revisiting the Roles of Filaggrin in Atopic Dermatitis

International Journal of Molecular Sciences, 2022
The discovery in 2006 that loss-of-function mutations in the filaggrin gene (FLG) cause ichthyosis vulgaris and can predispose to atopic dermatitis (AD) galvanized the dermatology research community and shed new light on a skin protein that was first ...
V. Moosbrugger-Martinz, C. Leprince, M. Méchin, M. Simon, S. Blunder, R. Gruber, S. Dubrac   +6 more
semanticscholar   +1 more source

Impact of Atopic Dermatitis on Work and Activity Impairment in Taiwan

Acta Dermato-Venereologica, 2021
Atopic dermatitis has a substantial impact on work and activity impairment according to studies from Western communities. Prospective studies of work productivity and activity impairment in Asian patients with atopic dermatitis are lacking.
Tom C. Chan, Yi-Chun Lin, Yung-Tsu Cho, Chao-Hsiun Tang, Chia-Yu Chu   +4 more
doaj   +1 more source

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA‐AD™): a clinical outcome measure for the severity of atopic dermatitis

British Journal of Dermatology, 2022
The validated Investigator Global Assessment for Atopic Dermatitis (vIGA‐AD™) is a standardized severity assessment for use in clinical trials and registries for atopic dermatitis (AD).
E. Simpson, R. Bissonnette, A. Paller, B. King, J. Silverberg, K. Reich, J. Thyssen, Helen Doll, Luna Sun, A. DeLozier, F. Nunes, L. Eichenfield   +11 more
semanticscholar   +1 more source

Annoying Psoriasis and Atopic Dermatitis: A Narrative Review

International Journal of Molecular Sciences, 2022
Skin is an important organ that mainly functions as a barrier. Skin diseases can damage a person’s self-confidence and reduce their willingness to socialize, as well as their social behavior and willingness.
Wei-Yu Chen, Shao-Chuan Chen, Shou-Yi Hsu, Yu-An Lin, Chun-Ming Shih, Chun-Yao Huang, Kuo‐Hsien Wang, Ai-Wei Lee   +7 more
semanticscholar   +1 more source